Thiamine (IV/IM — Pabrinex)
Brand names: Pabrinex IV High Potency
High-potency parenteral vitamin B and C (Pabrinex) given by IV infusion or IM injection to treat or prevent Wernicke's encephalopathy and other acute thiamine deficiency states. This page covers the parenteral replacement used in emergency care.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It supplies thiamine and other B-group vitamins that are essential cofactors for carbohydrate metabolism, replenishing stores rapidly enough to prevent the neurological damage of acute deficiency.
Prescribing in practice
- Anaphylaxis is the critical risk — give the IV preparation slowly and only where facilities to treat anaphylaxis are immediately available.
- Administer thiamine before or with any intravenous glucose in at-risk patients, as a glucose load can precipitate Wernicke's encephalopathy.
- Maintain a low threshold for treatment in alcohol dependence, malnutrition or persistent vomiting, where deficiency is easily missed.
Monitoring
Observe the patient during and after infusion for allergic reactions and monitor for resolution of neurological features.
Counselling the patient
- Explain this is a vitamin replacement given by drip or injection to protect the brain and nerves.
- Tell staff at once if you feel itchy, wheezy, light-headed or unwell during the infusion.
Evidence & guidelines
Parenteral thiamine for Wernicke's encephalopathy is supported by national guidance and longstanding clinical experience rather than large randomised trials.
Reference: NICE CG100 Alcohol Dependence; RCP Acute Care Handbook; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Framingham Risk Score · Cardiovascular Risk
- Boston Syncope Criteria · Syncope
- ARC-HBR Criteria for High Bleeding Risk in PCI · Coronary Artery Disease
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- PFO-Associated Stroke Causal Likelihood (PASCAL) Classification · Stroke Prevention
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
Thiamine (IV/IM — Pabrinex) is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.